$CYN
Cyngn Inc.

2022 Q3 Form 10-Q Financial Statement

#000121390022046890 Filed on August 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit $0.00 $0.00 $0.00
YoY Change
Gross Profit Margin
Selling, General & Admin $2.552M $2.357M $2.138M
YoY Change 162.07% 25.58%
% of Gross Profit
Research & Development $2.726M $2.256M $1.681M
YoY Change 136.81% 171.15%
% of Gross Profit
Depreciation & Amortization $42.29K $24.33K $69.05K
YoY Change 85.62% 10.37%
% of Gross Profit
Operating Expenses $5.278M $4.613M $3.819M
YoY Change 148.39% 120.33%
Operating Profit -$5.278M -$4.613M -$3.819M
YoY Change 148.39% 120.33%
Interest Expense $4.680K -$1.610K -$380.00
YoY Change -217.29% -73.34%
% of Operating Profit
Other Income/Expense, Net $18.97K $952.00 $0.00
YoY Change -36.46% -53.58%
Pretax Income -$5.259M -$4.612M -$3.819M
YoY Change 150.54% 26.58%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.259M -$4.612M -$3.819M
YoY Change 150.54% 120.5%
Net Earnings / Revenue
Basic Earnings Per Share -$0.16 -$0.15 -$0.14
Diluted Earnings Per Share -$0.16 -$0.15 -$142.2K
COMMON SHARES
Basic Shares Outstanding 33.63M shares 30.71M shares 26.86M shares
Diluted Shares Outstanding 33.64M shares 30.71M shares 26.86M shares

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.62M $32.60M $18.33M
YoY Change 1573.18% 857.64%
Cash & Equivalents $5.631M $5.602M $18.33M
Short-Term Investments $21.99M $27.00M
Other Short-Term Assets $586.8K $653.5K $635.9K
YoY Change 59.54% 34.14%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $28.21M $33.26M $18.97M
YoY Change 1297.38% 754.55%
LONG-TERM ASSETS
Property, Plant & Equipment $654.6K $467.7K $1.086M
YoY Change 832.54% 361.26%
Goodwill
YoY Change
Intangibles $364.4K $181.9K
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $1.527M $1.293M $1.116M
YoY Change 1397.24% 864.37%
TOTAL ASSETS
Total Short-Term Assets $28.21M $33.26M $18.97M
Total Long-Term Assets $1.527M $1.293M $1.116M
Total Assets $29.73M $34.55M $20.08M
YoY Change 1302.18% 758.21%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $299.1K $243.5K $94.69K
YoY Change 11.08% 87.26%
Accrued Expenses $47.39K $138.7K $720.1K
YoY Change -72.63% -40.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $32.61M $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $945.7K $1.086M $816.7K
YoY Change 93.87% 188.49%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $189.8K $228.7K
YoY Change
Total Long-Term Liabilities $0.00 $189.8K $228.7K
YoY Change -100.0% -88.13%
TOTAL LIABILITIES
Total Short-Term Liabilities $945.7K $1.086M $816.7K
Total Long-Term Liabilities $0.00 $189.8K $228.7K
Total Liabilities $945.8K $1.275M $1.045M
YoY Change -54.77% -35.42%
SHAREHOLDERS EQUITY
Retained Earnings -$130.2M -$124.9M
YoY Change
Common Stock $337.00 $336.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $22.00M
YoY Change
Treasury Stock Shares
Shareholders Equity $28.79M $33.27M $19.04M
YoY Change
Total Liabilities & Shareholders Equity $29.73M $34.55M $20.08M
YoY Change 1302.18% 758.21%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$5.259M -$4.612M -$3.819M
YoY Change 150.54% 120.5%
Depreciation, Depletion And Amortization $42.29K $24.33K $69.05K
YoY Change 85.62% 10.37%
Cash From Operating Activities -$4.596M -$3.602M -$3.400M
YoY Change 114.71% 1.65%
INVESTING ACTIVITIES
Capital Expenditures -$229.3K -$183.4K -$226.9K
YoY Change 3400.15% 1471.38%
Acquisitions
YoY Change
Other Investing Activities $4.839M -$27.15M
YoY Change 10153.4%
Cash From Investing Activities $4.609M -$27.34M -$226.9K
YoY Change 11241.83% 234149.61%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 16.51K 18.13M 88.89K
YoY Change -558.61% 1906.35%
NET CHANGE
Cash From Operating Activities -4.596M -3.602M -3.400M
Cash From Investing Activities 4.609M -27.34M -226.9K
Cash From Financing Activities 16.51K 18.13M 88.89K
Net Change In Cash 29.47K -12.81M -3.538M
YoY Change -101.4% 382.91%
FREE CASH FLOW
Cash From Operating Activities -$4.596M -$3.602M -$3.400M
Capital Expenditures -$229.3K -$183.4K -$226.9K
Free Cash Flow -$4.367M -$3.419M -$3.173M
YoY Change 104.63% -3.21%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40932
dei Entity Registrant Name
EntityRegistrantName
CYNGN INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-2007094
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Entity Address Address Line1
EntityAddressAddressLine1
1015 O’Brien Dr.
dei Entity Address City Or Town
EntityAddressCityOrTown
Menlo Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94025
dei City Area Code
CityAreaCode
(650)
dei Local Phone Number
LocalPhoneNumber
924-5905
dei Security12b Title
Security12bTitle
Common stock, $0.00001
dei Trading Symbol
TradingSymbol
CYN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
33627562 shares
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5601774 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21945981 usd
CY2022Q2 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000 usd
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000 usd
CY2022Q2 us-gaap Short Term Investments
ShortTermInvestments
27000015 usd
CY2022Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
603508 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
525304 usd
CY2022Q2 us-gaap Assets Current
AssetsCurrent
33255297 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
22521285 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
467671 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
102787 usd
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
265 usd
CY2022Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
643183 usd
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
181880 usd
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
30917 usd
CY2022Q2 us-gaap Assets
Assets
34548031 usd
CY2021Q4 us-gaap Assets
Assets
22654989 usd
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
243531 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
112271 usd
CY2022Q2 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
386605 usd
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
295156 usd
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
455545 usd
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1085681 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
407427 usd
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
189811 usd
CY2022Q2 us-gaap Liabilities
Liabilities
1275492 usd
CY2021Q4 us-gaap Liabilities
Liabilities
407427 usd
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.00001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
33575334 shares
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
33575334 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26487680 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26487680 shares
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
336 usd
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
158196733 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
138740827 usd
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-124924530 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116493530 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
33272539 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22247562 usd
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
34548031 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22654989 usd
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2255666 usd
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
831896 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3936811 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1766186 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2357247 usd
CY2021Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1261727 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4494763 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1877118 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
4612913 usd
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
2093623 usd
us-gaap Operating Expenses
OperatingExpenses
8431574 usd
us-gaap Operating Expenses
OperatingExpenses
3643304 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-4612913 usd
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2093623 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8431574 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-3643304 usd
CY2022Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1607 usd
CY2021Q2 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-3901 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
19037550 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-1986 usd
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-6043 usd
CY2022Q2 us-gaap Other Income
OtherIncome
2559 usd
CY2021Q2 us-gaap Other Income
OtherIncome
5952 usd
us-gaap Other Income
OtherIncome
2560 usd
us-gaap Other Income
OtherIncome
5952 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
952 usd
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2051 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
574 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-91 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4611961 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2091572 usd
us-gaap Net Income Loss
NetIncomeLoss
-8431000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3643395 usd
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.2
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.83
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30706235 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
951794 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
28682245 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
951794 shares
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
8773 usd
CY2022Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
11989509 usd
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6132436 usd
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
2662 usd
CY2022Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
713570 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-4611961 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
33272539 usd
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
4053771 usd
CY2021Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
88198 usd
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-2091572 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2050397 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
22247562 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
97658 usd
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
11989509 usd
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
2662 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1233712 usd
us-gaap Net Income Loss
NetIncomeLoss
-8431000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
33272539 usd
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
5597734 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
96058 usd
us-gaap Net Income Loss
NetIncomeLoss
-3643395 usd
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
2050397 usd
us-gaap Net Income Loss
NetIncomeLoss
-8431000 usd
us-gaap Net Income Loss
NetIncomeLoss
-3643395 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
903802 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
97658 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
18222265 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
229102 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
45818 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1233712 usd
us-gaap Share Based Compensation
ShareBasedCompensation
96058 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
902512 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
38329 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
131260 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
57036 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
736805 usd
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-61126 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7002633 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3543938 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
410289 usd
us-gaap Payments To Acquire Equity Method Investments
PaymentsToAcquireEquityMethodInvestments
7523 usd
cyngn Proceed From Sale Of Other Productive Assets
ProceedFromSaleOfOtherProductiveAssets
4150 usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
153550 usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
27000000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27563839 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-11673 usd
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
18121945 usd
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2662 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
903802 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-16344207 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-2651809 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21995981 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6456190 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5651774 usd
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3804381 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
824292 usd
cyngn Change In Deferred Rent Associated With
ChangeInDeferredRentAssociatedWith
58676 usd
cyngn Acquisition Of Property And Equipment Included In Accounts Payable And Accrued Expenses
AcquisitionOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses
22185 usd
CY2021Q4 cyngn Purchase An Additional Shares Of Common Stock
PurchaseAnAdditionalSharesOfCommonStock
525000 shares
CY2022Q2 us-gaap Excess Stock Shares Authorized
ExcessStockSharesAuthorized
110000000 shares
CY2022Q2 cyngn Common Stock Shares
CommonStockShares
100000000 shares
CY2022Q2 cyngn Preferred Stock Share Issued
PreferredStockShareIssued
10000000 shares
CY2022Q2 us-gaap Preferred Stock Redemption Price Per Share
PreferredStockRedemptionPricePerShare
0.00001
us-gaap Conversion Of Stock Description
ConversionOfStockDescription
Pursuant to the Purchase Agreement, the Company sold (i) 3,790,322 shares of its Common Stock together with Common Warrants to purchase up to 3,790,322 shares of Common Stock, and (ii) 2,661,291 Pre-Funded Warrants with each Pre-Funded Warrant exercisable for one share of Common Stock, together with Common Warrants to purchase up to 2,661,291 shares of Common Stock.
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
6451613 shares
cyngn Offering Price
OfferingPrice
3.09
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
2.98
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
488767 usd
CY2022Q2 us-gaap Long Term Debt Term
LongTermDebtTerm
P5Y
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
431385 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
8400000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
3600000 usd
CY2022Q2 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
125000000 usd
CY2021Q4 us-gaap Retained Earnings Appropriated
RetainedEarningsAppropriated
116500000 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
7000000 usd
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
3500000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
385980 usd
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
467671 usd
us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Use of Estimates</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the balance sheet date, as well as reported amounts of revenue and expenses during the reporting period. The Company’s significant estimates and judgments include but are not limited to share-based compensation. Management bases its estimates on historical experience and on various other assumptions believed to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Concentration of Credit Risk</i></b></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents. The Company’s cash is placed with high-credit-quality financial institutions and issuers, and at times exceeds federally insured limits. The Company limits its concentration of risk in cash equivalents by diversifying its investments among a variety of industries and issuers. The Company has not experienced any credit loss relating to its cash equivalents.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Cash and cash equivalents maintained with domestic commercial banks generally exceed the Federal Deposit Insurance Corporation insurable limit. To date, the Company has not experienced any losses on its deposits of cash and cash equivalents. Cyngn invests in U.S. Treasury securities and carries these at amortized cost and recognizes gains and losses when realized.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"/>
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
102787 usd
CY2022Q2 cyngn Unrestricted Cash And Cash Equivalents
UnrestrictedCashAndCashEquivalents
5600000 usd
CY2021Q4 cyngn Unrestricted Cash And Cash Equivalents
UnrestrictedCashAndCashEquivalents
21900000 usd
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
50000 usd
CY2022Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
5601774 usd
CY2021Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
3404381 usd
CY2022Q2 us-gaap Restricted Cash
RestrictedCash
50000 usd
CY2021Q2 us-gaap Restricted Cash
RestrictedCash
400000 usd
CY2022Q2 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
5651774 usd
CY2021Q2 us-gaap Restricted Cash And Investments Current
RestrictedCashAndInvestmentsCurrent
3804381 usd
CY2022Q2 us-gaap Depreciation
Depreciation
24330 usd
CY2022Q2 us-gaap Supplemental Deferred Purchase Price
SupplementalDeferredPurchasePrice
100000 usd
CY2022Q2 us-gaap Bank Overdrafts
BankOverdrafts
5651774 usd
CY2022Q2 us-gaap Us Government Securities At Carrying Value
USGovernmentSecuritiesAtCarryingValue
26958781 usd
CY2022Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
32610555 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
41233 usd
us-gaap Dividends
Dividends
15 usd
CY2021Q4 us-gaap Bank Overdrafts
BankOverdrafts
21995981 usd
CY2021Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
21995981 usd
CY2022Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
899056 usd
CY2022Q2 cyngn Automobiles
Automobiles
361724 usd
CY2021Q4 cyngn Automobiles
Automobiles
279617 usd
CY2022Q2 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
139501 usd
CY2021Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
133102 usd
CY2022Q2 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
276257 usd
CY2021Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
76048 usd
CY2022Q2 us-gaap Public Utilities Property Plant And Equipment Construction Work In Progress
PublicUtilitiesPropertyPlantAndEquipmentConstructionWorkInProgress
121574 usd
CY2021Q2 us-gaap Depreciation
Depreciation
22044 usd
us-gaap Depreciation
Depreciation
45405 usd
us-gaap Depreciation
Depreciation
44086 usd
CY2022Q2 cyngn Credit Card Payable
CreditCardPayable
6750 usd
CY2021Q4 cyngn Credit Card Payable
CreditCardPayable
11678 usd
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
138734 usd
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
82478 usd
CY2022Q2 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
241121 usd
CY2021Q4 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
201000 usd
CY2022Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
386605 usd
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
295156 usd
CY2021Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
67958 usd
CY2022Q2 us-gaap Receivable With Imputed Interest Net Amount
ReceivableWithImputedInterestNetAmount
16380 usd
CY2022Q2 us-gaap Present Value Of Future Minimum Lease Payments Sale Leaseback Transactions
PresentValueOfFutureMinimumLeasePaymentsSaleLeasebackTransactions
645356 usd
cyngn Rent Expense
RentExpense
47000 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
279410 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
382326 usd
CY2022Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
661736 usd
CY2022Q2 cyngn Operating Leases Liability Current
OperatingLeasesLiabilityCurrent
455545 usd
CY2022Q2 cyngn Operating Leases Liability Noncurrent
OperatingLeasesLiabilityNoncurrent
189811 usd
CY2022Q2 cyngn Operating Lease Liabilities Net
OperatingLeaseLiabilitiesNet
645356 usd
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M1D
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0344 pure
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
157869 usd
CY2021Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
75287 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
235968 usd
us-gaap Operating Lease Expense
OperatingLeaseExpense
114882 usd
CY2022Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
133998 usd
CY2021Q2 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
181110 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
0 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
205550 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-23670 usd
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
181880 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
52000 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
-21083 usd
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
30917 usd
CY2022Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
1720 usd
CY2021Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
866 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
2587 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
1733 usd
CY2020Q2 us-gaap Other Borrowings
OtherBorrowings
695078 usd
CY2020Q2 us-gaap Investment Interest Rate
InvestmentInterestRate
0.0098 pure
CY2020Q2 cyngn Maturity Date
MaturityDate
P24M
CY2021Q1 us-gaap Investment Owned Balance Principal Amount
InvestmentOwnedBalancePrincipalAmount
892115 usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.95
cyngn Stocks Issued During Period Shares Stock Options Exercised
StocksIssuedDuringPeriodSharesStockOptionsExercised
636041 shares
CY2021Q1 cyngn Maturity Date
MaturityDate
P5Y
CY2021Q1 us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.0098 pure
CY2021Q4 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
33575334 shares
CY2022Q2 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
33575334 shares
CY2021Q4 us-gaap Excess Stock Shares Outstanding
ExcessStockSharesOutstanding
26487680 shares
CY2022Q2 us-gaap Excess Stock Shares Outstanding
ExcessStockSharesOutstanding
26487680 shares
CY2021Q2 us-gaap Preferred Units Authorized
PreferredUnitsAuthorized
21982491 shares
CY2021Q2 cyngn Preferred Stock Par Or State Value Per Share
PreferredStockParOrStateValuePerShare
0.00001
CY2022Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
21982491 shares
CY2022Q2 cyngn Series A Shares Issued And Outstanding
SeriesASharesIssuedAndOutstanding
21982491 shares
us-gaap Preferred Stock Amount Of Preferred Dividends In Arrears
PreferredStockAmountOfPreferredDividendsInArrears
112265042 usd
CY2022Q2 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
112265042 usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.15
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
931660 usd
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
15746916 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1384500 shares
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4611961 usd
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2091572 usd
CY2022Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
30706235 shares
CY2021Q2 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
951794 shares
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.15
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.2
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8431000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3643395 usd
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
26682245 shares
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
951794 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.83
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
9708436 usd
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans
5923887 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
8911339 shares
CY2021Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
10877419 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
21982491 shares
cyngn Earnings Per Share Total
EarningsPerShareTotal
18619775 shares
cyngn Earnings Per Share Total
EarningsPerShareTotal
38783797 shares
cyngn Fair Value Is Recognized
FairValueIsRecognized
The resulting fair value is recognized on a straight-line basis over the period during which an employee is required to provide service in exchange for the award. The Company has elected to recognize forfeitures as they occur. Stock options generally vest over four years and have a contractual term of ten years.
cyngn Common Stock Shares Issurance
CommonStockSharesIssurance
8911339 shares
CY2021 cyngn Common Stock Shares Issurance
CommonStockSharesIssurance
10502696 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8769694 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.2
CY2021Q4 cyngn Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
P7Y1M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
50209 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.88
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9467944 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.37
CY2022Q2 cyngn Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5082634 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
9467944 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.37
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y2M12D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
5082634 usd
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
5409688 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0.37
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y7M17D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
5019382 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
244566 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
4074 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
5.52
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
240492 shares
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
5.52
cyngn Weighted Average Per Share Grantdate Fair Value Of Options Granted
WeightedAveragePerShareGrantdateFairValueOfOptionsGranted
0.77
cyngn Weighted Average Per Share Grantdate Fair Value Of Options Granted
WeightedAveragePerShareGrantdateFairValueOfOptionsGranted
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.95
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y21D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0249 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.3623 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2022Q2 cyngn Stockbased Compensation Expense From Stock Options
StockbasedCompensationExpenseFromStockOptions
713570 usd
cyngn Stockbased Compensation Expense From Stock Options
StockbasedCompensationExpenseFromStockOptions
88198 usd
cyngn Stockbased Compensation Expense From Stock Options
StockbasedCompensationExpenseFromStockOptions
1233712 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
96058
us-gaap Present Value Of Future Insurance Profits Weighted Average Amortization Period
PresentValueOfFutureInsuranceProfitsWeightedAverageAmortizationPeriod
P3Y8M12D
us-gaap Revenues
Revenues
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0 pure
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0 pure
CY2021Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0 pure
CY2022Q2 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0 pure
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.83
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
951794 shares
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
6.132436 usd
cyngn Proceed From Sale Of Other Productive Assets
ProceedFromSaleOfOtherProductiveAssets
usd
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
usd
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
cyngn Change In Deferred Rent Associated With
ChangeInDeferredRentAssociatedWith
usd
CY2021Q4 us-gaap Public Utilities Property Plant And Equipment Construction Work In Progress
PublicUtilitiesPropertyPlantAndEquipmentConstructionWorkInProgress
usd
us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
shares
cyngn Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm1
cyngn Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercised Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisedWeightedAverageRemainingContractualTerm1
cyngn Sharebased Compensation Arrangement By Sharebased Payment Award Options Cancelled Forfeited Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsCancelledForfeitedWeightedAverageRemainingContractualTerm1
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001874097

Files In Submission

Name View Source Status
0001213900-22-046890-index-headers.html Edgar Link pending
0001213900-22-046890-index.html Edgar Link pending
0001213900-22-046890.txt Edgar Link pending
0001213900-22-046890-xbrl.zip Edgar Link pending
cyngn-20220630.xsd Edgar Link pending
f10q0622ex31-1_cyngninc.htm Edgar Link pending
f10q0622ex31-2_cyngninc.htm Edgar Link pending
f10q0622ex32-1_cyngninc.htm Edgar Link pending
f10q0622_cyngninc.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
cyngn-20220630_cal.xml Edgar Link unprocessable
cyngn-20220630_def.xml Edgar Link unprocessable
cyngn-20220630_lab.xml Edgar Link unprocessable
cyngn-20220630_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
f10q0622_cyngninc_htm.xml Edgar Link completed
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending